INT164258

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.47
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 6
Disease Relevance 0.55
Pain Relevance 0.65

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (GLA) extracellular region (GLA) Golgi apparatus (GLA)
lysosome (GLA) cytoplasm (GLA)
GLA (Homo sapiens)
Pain Link Frequency Relevance Heat
Duloxetine 1 100.00 Very High Very High Very High
dexamethasone 2 98.20 Very High Very High Very High
Adalimumab 1 90.42 High High
Gabapentin 3 88.84 High High
Nicotine 48 77.00 Quite High
Glutamate 84 73.60 Quite High
Morphine 1 69.44 Quite High
pregabalin 2 60.60 Quite High
agonist 54 50.72 Quite High
Pain 42 38.80 Quite Low
Disease Link Frequency Relevance Heat
Papillomavirus Infection 1 87.56 High High
Targeted Disruption 46 78.64 Quite High
Lysosome Storage Disease 12 74.88 Quite High
Fabry Disease 220 70.00 Quite High
Body Weight 5 50.08 Quite High
Disease 54 42.76 Quite Low
Pain 48 38.80 Quite Low
Chronic Renal Failure 16 33.04 Quite Low
Renal Disease 27 5.00 Very Low Very Low Very Low
Proteinuria 23 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Here, a promoter activator binds the GLA promoter in the nuclei of cells and enhances GLA transcription, thereby increasing the synthesis of mutant GLA protein.
Positive_regulation (increasing) of Gene_expression (synthesis) of GLA
1) Confidence 0.47 Published 2010 Journal Current Chemical Genomics Section Body Doc Link PMC2995157 Disease Relevance 0.27 Pain Relevance 0
DGJ may be effective only in patients with specific, "responsive" GLA mutations coding for a mutant ?
Positive_regulation (responsive) of Gene_expression (mutations) of GLA
2) Confidence 0.43 Published 2010 Journal Orphanet J Rare Dis Section Body Doc Link PMC3009617 Disease Relevance 0.05 Pain Relevance 0
This is further supported by the observations that GalA-MRP produced increase in human sensory salt taste evaluation in the presence of amiloride (Figure 8B).
Positive_regulation (increase) of Gene_expression (produced) of GalA
3) Confidence 0.12 Published 2008 Journal Chemical Senses Section Body Doc Link PMC2533421 Disease Relevance 0 Pain Relevance 0.09
At all temperatures studied, GalA-MRP produced a significantly greater increase (P < 0.0001) in the tonic CT response (N + Bz + GalA-MRP) relative to (N + Bz) (Figure 3B).
Positive_regulation (increase) of Gene_expression (produced) of GalA
4) Confidence 0.12 Published 2008 Journal Chemical Senses Section Body Doc Link PMC2533421 Disease Relevance 0 Pain Relevance 0.06
GalA-MRP produced maximum increase in the CT response between pH 6 and 7.
Positive_regulation (increase) of Gene_expression (produced) of GalA
5) Confidence 0.12 Published 2008 Journal Chemical Senses Section Body Doc Link PMC2533421 Disease Relevance 0.14 Pain Relevance 0.13
This issue focuses on the following selection of drugs: AAV1/SERCA2a, Abacavir sulfate/lamivudine, Adalimumab, Aliskiren fumarate, Ambrisentan, Aripiprazole, AT-7519, Atazanavir sulfate, Atomoxetine hydrochloride, Azacitidine, Azelnidipine; Besifloxacin hydrochloride, Bevacizumab, Bioabsorbable everolimus-eluting coronary stent, Bortezomib, Bosentan, Budesonide/formoterol fumarate; CAIV-T, Carisbamate, Casopitant mesylate, Certolizumab pegol, Cetuximab, Ciclesonide, Ciprofloxacin/dexamethasone, CTCE-9908; Dalcetrapib, Darunavir, Deferasirox, Desloratadine, Disitertide, Drotrecogin alfa (activated), DTA-H19, Duloxetine hydrochloride, Dutasteride; Ecogramostim, Efalizumab, Emtricitabine, Eribulin mesilate, Escitalopram oxalate, Eszopiclone, EUR-1008, Everolimus-eluting coronary stent, Exenatide; Fampridine, Fluticasone furoate, Formoterol fumarate/fluticasone propionate, Fosamprenavir calcium, Fulvestrant; Gabapentin enacarbil, GS-7904L; HPV-6/11/16/18, Human Secretin, Hydralazine hydrochloride/isosorbide dinitrate; Imatinib mesylate, Imexon, Inalimarev/Falimarev, Indacaterol, Indacaterol maleate, Inhalable human insulin, Insulin detemir, Insulin glargine, Ixabepilone; L-Alanosine, Lapatinib ditosylate, Lenalidomide, Levocetirizine dihydrochloride, Liraglutide, Lisdexamfetamine mesilate, Lopinavir, Loratadine/montelukast sodium, Lutropin alfa; MeNZB, Mepolizumab, Micafungin sodium, Morphine hydrochloride; Nabiximols, Nikkomycin Z; Olmesartan medoxomil, Omalizumab; Paclitaxel-eluting stent, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Perifosine, PF-489791, Plitidepsin, Posaconazole, Pregabalin; QAX-576; Raltegravir potassium, Ramelteon, Rasagiline mesilate, Recombinant human relaxin H2, rhGAD65, Rivaroxaban, Rosuvastatin calcium, Rotigotine; Saxagliptin, SCH-530348, Sirolimus-eluting stent, SLIT-amikacin, Sorafenib, Sotrastaurin, SR-16234, Sulforaphane; Tadalafil, Tanespimycin, Tapentadol hydrochloride, Teriparatide, Tesofensine, Tiotropium bromide, Tipifarnib, Tirapazamine, TMC-207, Tocilizumab, Tolvaptan, Tosedostat, Treprostinil sodium; Ustekinumab; Varespladib methyl, Vicriviroc, Vildagliptin, Vildagliptin/metformin hydrochloride, Volociximab, Voriconazole; Ziconotide, Ziprasidone hydrochloride.
Positive_regulation (activated) of Gene_expression (hydrochloride) of alfa associated with pregabalin, papillomavirus infection, ziconotide, adalimumab, gabapentin, duloxetine, dexamethasone and morphine
6) Confidence 0.05 Published 2009 Journal Methods Find Exp Clin Pharmacol Section Abstract Doc Link 19907722 Disease Relevance 0.09 Pain Relevance 0.36

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox